The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature

• Main Authors: S. Barsotti (Author), E. Cioffi (Author), A. Tripoli (Author), A. Tavoni (Author), A. d'Ascanio (Author), M. Mosca (Author), R. Neri (Author)
• Format: Book
• Published: PAGEPress Publications, 2018-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Rituximab (RTX), a chimeric monoclonal antibody targeted against CD20, has been used to treat refractory inflammatory myopathies (IIM). The primary objective of this study was to retrospectively assess the efficacy of RTX in reducing disease activity in patients with IIM refractory to conventional t...